It is noteworthy that these improvements occurred despite the participant being treated with dulaglutide since 2022, a GLP-1 receptor agonist that has been shown in recent reports to significantly reduce depressive symptoms in individuals living with diabetes (11). Here, GLP1R is linked to diabetes mellitus.